Adverse Drug Interactions Clinically Important for the Dermatologist

Archives of Dermatology

Volumn 131, Issue 4, 1995, Pages 468-473

  Andersen, William K ^a   Feingold, David S ^b,c  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN A; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; ETRETINATE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PREDNISONE; PROGESTERONE; RETINOID; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; TERBINAFINE; TERFENADINE; TRIMETHOPRIM; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; BONE MARROW TOXICITY; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; PRIORITY JOURNAL; SEIZURE; SKIN DISEASE; TORSADE DES POINTES;

ANTIBIOTICS; ANTIFUNGAL AGENTS; CYCLOSPORINE; DERMATOLOGY; DRUG INTERACTIONS; HISTAMINE ANTAGONISTS; HUMAN; METHOTREXATE; PHARMACEUTICAL PREPARATIONS; RETINOIDS; RISK FACTORS;

EID: 0028915919     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1995.01690160098017     Document Type: Article

References (72)

1. 1. Brodie MJ, Feely J. Adverse drug interactions. BMJ. 1988; 296: 845-849.
2. 2. Shin AF, ed. Evaluation of Drug Interactions. New York, NY: Macmillan Publishing Co; 1988.
3. 3. Tatro DS. Drug Interaction Facts. 2nd ed. Philadelphia, Pa: JB Lippincott Co; 1990.
4. 4. Hansten PD, Horn JR, eds. Clinical Significance of DDIs. 6th ed. Philadelphia, Pa: Lea & Febiger; 1993.
5. 5. Hansten PD, Horn JR, Koda-Kimble MA, eds. Drug Interactions and Updates Quarterly. Vancouver, Wash: Applied Therapeutics; 1993.
6. 6. Kessler DA. Introducing Medwatch: a new approach to reporting medication and device adverse effects and product problems. JAMA. 1993; 269: 2765-2768.
7. 7. Blaschke TF, Cohen SN, Tatro DS, Rubin PC. Drug-drug interactions and aging. In: Jarvik LF, Greenblatt DJ, Harman D, eds. Clinical Pharmacology and the Aged Patient. New York, NY: Raven Press; 1981; 16: 11-24.
8. 8. Stockley IH. Drug Interactions. London, England: Blackwell Scientific Publications; 1991: 1-13.
9. 9. Schentag JJ, Goss TF. Quinolone pharmacokinetics in the elderly. Am J Med. 1992; 92(suppl): 33S-37S.
10. 10. Brown GR, Minata M, McCormack JP. Drug concentration monitoring. Clin Pharmacokinet 1993; 24: 187-194.
11. 11. Belle LL, Safrin S. Drug interactions and toxicities in patients with AIDS. Curr Opin Infect Dis. 1992; 5: 231-240.
12. 12. Bint AJ, Burtt I. Adverse antibiotic interactions. Drugs. 1980; 20: 57-68.
13. 13. Jahnchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol. 1978; 5: 437-440.
14. 14. Erttmann R, Landbeck G. Effect of oral cholestyramine on the elimination of high-dose methotrexate. J Cancer Res Clin Oncol. 1985; 110: 48-50.
15. 15. Stockley IH. Drug Interactions. London, England: Blackwell Scientific Publications; 1991: 380-381.
16. 16. Bodey GP. Azole antifungal drugs. Clin Infect Dis. 1992; 14: 5161-5169.
17. 17. Wellint PG. Interactions affecting drug absorption. Clin Pharmacokinet. 1984; 9: 404-435.
18. 18. Wrighton SA, Stevens JC. The human hepatic cytochrome P-450s involved in drug metabolism. Crit Rev Toxicol. 1992; 22: 1-21.
19. 19. Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol. 1990; 23: 1301-1311.
20. 20. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet. 1981; 6: 1-24.
21. 21. Pichard L, Fabre I, Fabre G, et al. Cyclosporin-A drug interactions. Drug Metab Dispos. 1990; 18: 390-401.
22. 22. Bruce S, Wolf JE. Antimicrobial agents. In: Wolverton SE, Wilkin JK, eds. Systemic Drugs for Skin Diseases. Philadelphia, Pa: WB Saunders Co; 1991: 52-55.
23. 23. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet. 1992; 23: 106-131.
24. 24. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977; 4: 87-101.
25. 25. Stockley IH. Drug Interactions. London, England: Blackwell Scientific Publications; 1991: 363-364.
26. 26. Liegler DC, Henderson ES, Hahn MA, Oliverio VT. The effect of organic acids on methotrexate excretion in man. Clin Pharmacol Ther. 1969; 10: 849-857.
27. 27. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum. 1991; 34: 1514-1520.
28. 28. Govert JA, Patton S, Fine RL. Pancytopenia from using trimethoprim and methotrexate. Ann Intern Med. 1992; 117: 877-878.
29. 29. Liddle BJ, Marsden JR. Drug interactions with methotrexate. Br J Dermatol. 1989; 120: 582.
30. 30. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving TMP-SMX. J Rheum. 1986; 13: 440-441.
31. 31. Kobrinsky NL, Ramsay NK. Acute megaloblastic anemia induced by high dose TMP-SMX. Ann Intern Med. 1981; 94: 780-781.
32. 32. Larsen FG, Nielsen-Kudsk F, Jakobsen P, Schroder H, Kragballe K. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol. 1990; 30: 802-807.
33. 33. Korstanje MJ, Vriesman CJ, Staak WJ. Cyclosporin and methotrexate: a dangerous combination. J Am Acad Dermatol. 1990; 23: 320-321.
34. 34. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin, and ethoxycoumarin by human liver microsomes in vitro. Br J Pharmacol. 1989; 28: 166-170.
35. 35. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol. 1991; 32: 624-626.
36. 36. Stockley IH. Drug Interactions. London, England: Blackwell Scientific Publications; 1991: 451.
37. 37. Webber IR, Back DJ. Effect of etretinate on cyclosporin metabolism in vitro. Br J Dermatol. 1993; 128: 42-44.
38. 38. Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother. 1990; 34: 2032-2033.
39. 39. Trenk D, Brett W, Jahnchen E, Birnbaum D. Time course of cyclosporin/ itraconazole interaction. Lancet. 1987; 2: 1335-1336.
40. 40. Sugar AM, Saunders C, Idelson BA, Bernard DB. Interaction of fluconazole and cyclosporine. Ann Intern Med. 1989; 110: 844.
41. 41. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992; 14: 165-174.
42. 42. Cullen SI, Catalano PM. Griseofulvin-warfarin antagonism. JAMA. 1967: 199: 482-483.
43. 43. Van Dijke CP, Weber JC. Interaction between oral contraceptives and griseofulvin. BMJ. 1984; 288: 1125-1126.
44. 44. Cote J. Interaction of griseofulvin and oral contraceptives. J Am Acad Dermatol. 1990; 22: 124-125.
45. 45. Riegelman S, Rowland M, Epstein WL. Griseofulvin-phenobarbital interaction in man. JAMA. 1970; 213: 426-431.
46. 46. Phillips KR, Wideman SD, Cochran EB, Becker JA. Griseofulvin significantly decreases serum salicylate concentrations. Pediatr Infect Dis J. 1993; 12: 350-352.
47. 47. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by drithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother. 1993; 37: 265-269.
48. 48. Maxwell DL, Gilmour-White SK, Hall MR. Digoxin toxicity due to interaction of digoxin with erythromycin. BMJ. 1989; 298: 572.
49. 49. Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981; 305: 305: 789-794.
50. 50. Basler RSW, Goetz CS. Synergy of minocycline and amitriptyline in cutaneous hyperpigmentation. J Am Acad Dermatol. 1985; 12: 577.
51. 51. Feingold DS, Wagner RF Jr. Antibacterial therapy. J Am Acad Dermatol. 1986; 14: 535-548.
52. 52. Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis. 1992; 14: 272-284.
53. 53. Grasela TH, Dreis MW. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous sorting system. Arch Intern Med. 1992; 152: 617-621.
54. 54. Stockley IH. Tetracycline and oral contraceptives. J Am Acad Dermatol. 1982; 7: 279-280.
55. 55. Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril. 1988; 495(suppl): 31S-38S.
56. 56. Rasmussen JE. The effect of antibiotics on the efficacy of oral contraceptives. Arch Dermatol. 1989; 125: 1562-1564.
57. 57. Shalita AR, Cunningham WJ, Leyden JJ, Pochi JE, Strauss JS. Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol. 1983; 9: 629-638.
58. 58. Rollman O, Vahlquist A. Interactions of retinoids with other systemically administered drugs. Dermatol Today Tomorrow. 1992; 28: 4-7.
59. 59. Osterle LS, Langtry JA, Jones S, Staughton RC. Reduced therapeutic effect of warfarin caused by etretinate. Br J Dermatol. 1991; 124: 505-510.
60. 60. Chou RC, Wyss R, Huselton CA, Wiegand UW. A newly discovered xenobiotic pathway: ethyl ester formation. Life Sci. 1991; 49: PL169-PL172.
61. 61. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol. 1993; 100: 623-627.
62. 62. FDA Med Bull. 1993; 23: 2-3.
63. 63. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA. 1993; 269: 1513-1518.
64. 64. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. BMJ. 1993; 306: 186.
65. 65. Barone JA. Pharmacokinetic profiles of astemizole and terfenadine. Antihistamine Consensus Conference. 1993; 13-16.
66. 66. Del Rosso JQ. Antihistamines. In: Wolverton SE, Wilkin JK, eds. Systemic Drugs for Skin Diseases. Philadelphia, Pa: WB Saunders Co; 1991: 285-326.
67. 67. Somogyi A, Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet. 1982; 7: 23-41.
68. 68. Henauer SA, Hollister LE. Cimetidine interaction with imiprimine and nortryptiline. Clin Pharmacol Ther. 1984; 35: 183-187.
69. 69. Stockley IH. Drug Interactions. London, England: Blackwell Scientific Publications; 1991: 612.
70. 70. Younger IR, Harris DW, Colver GB. Azathioprine in dermatology. J Am Acad Dermatol. 1991; 25: 281-286.
71. 71. Dzubow LM. The interaction between propranolol and epinephrine as observed in patients undergoing Mohs' surgery. J Am Acad Dermatol. 1986; 15: 71-75.
72. 72. Stern RS, Kleinerman RA, Parrish JA, et al. Phototoxic reactions to photoactive drugs in patients treated with PUVA. Arch Dermatol. 1980; 116: 1269-1271.